Immunological Surveillance Versus Immunological Stimulation of Oncogenesis- a Formal Proof of the Stimulation Hypothesis

  • Richmond T. Prehn
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 155)


When I was first introduced to cancer research in 1949, the immune mechanism was characterized by the attributes of specificity and memory, and the function of the thymus was unknown. We now have some knowledge of the role of the thymus and the definition of an immune reaction seems to have undergone a radical change. For example, a cell of the lymphoid family that has little specificity and is apparently unassociated with any form of memory, the so-called NK cell, is now promoted as the possible agent of immunological surveillance. Apparently, any function of any leucocyte is now deemed to be immunologic regardless of questions of specificity or memory.


Short Latency Primary Host Immunogenic Tumor Secondary Host Immunological Surveillance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Prehn, R. T., and Main, J. M., J. Nat. Cancer Inst. 18:769, 1957.PubMedGoogle Scholar
  2. 2.
    Klein, G., Sjögren, H. O., Klein, E., and Hellström, K. E., Cancer Res. 20:1561, 1960.PubMedGoogle Scholar
  3. 3.
    Basombrio, M. A., and Prehn, R. T., Cancer Res. 32:2545, 1972.PubMedGoogle Scholar
  4. 4.
    Old, L. J., Boyse, E. A., Clarke, D. A., and Carswell, E. A., Ann. N. Y. Acad. of Sci. 101:80, 1962.CrossRefGoogle Scholar
  5. 5.
    Marchant, J., Brit. J. Cancer 23:383, 1969.PubMedCrossRefGoogle Scholar
  6. 6.
    Bonmassar E., Menconi, E., Goldin, A., and Cudkowicz, G., J. Nat. Cancer Inst. 53:475, 1974.PubMedGoogle Scholar
  7. 7.
    Prehn, R. T., J. Nat. Cancer Inst. 55:189, 1975.PubMedGoogle Scholar
  8. 8.
    Burnet, F. M., Prog. Exp. Tumor Res. 13:1, 1970.PubMedGoogle Scholar
  9. 9.
    Thomas, L., in “Cellular and Humoral Aspects of the Hypersensitive States” (H. S. Lawrence, ed.), pp. 529–532, Hoeber, New York, 1959.Google Scholar
  10. 10.
    Law, L. W., Cancer Res. 26:551, 1966.PubMedGoogle Scholar
  11. 11.
    Law, L. W., Cancer Res. 26:1121, 1966.PubMedGoogle Scholar
  12. 12.
    Grant, G., Roe, F. J., and Pike, M. C., Nature 210:603, 1966.PubMedCrossRefGoogle Scholar
  13. 13.
    Penn, I., and Starzl, T. E., Transplantation 14:407, 1972.PubMedCrossRefGoogle Scholar
  14. 14.
    Weston, B. J., in “Contemp. Topics Immunobiol.” (A. J. S. Davies and R. L. Carter, eds.), pp. 237–252, Plenum Press, New York, 1973, Vol. 2.Google Scholar
  15. 15.
    Outzen, H. C., Custer, R. P., Eaton, G. T., and Prehn, R. T., J. Reticuloendothelial Soc. 17:1, 1975.Google Scholar
  16. 16.
    Stutman, O., Science 183:534, 1974.PubMedCrossRefGoogle Scholar
  17. 17.
    Prehn, R. T., J. Reticuloendothelial Soc. 10:1, 1971.Google Scholar
  18. 18.
    Prehn, R. T., and Lappé, M. A., Transplantation Rev. 7:26, 1971.Google Scholar
  19. 19.
    Prehn, R. T., and Outzen, H. C., In “Prog, in Immunology IV, Immunology’ 80”. (M. Fougereau and J. Dausset, eds.), pp. 651–658, Academic Press, London, 1980.Google Scholar
  20. 20.
    Lawler, E. M., Outzen, H. C., and Prehn, R. T., Cancer Imm. and Immunotherapy 11:87, 1981.Google Scholar
  21. 21.
    Johnson, S., Brit. J. Cancer 22:93, 1968.PubMedCrossRefGoogle Scholar
  22. 22.
    Bartlett, G. L., J. Nat. Cancer Inst. 49:493, 1972.PubMedGoogle Scholar
  23. 23.
    Nebert, D. W., Robinson, J. R., Niwa, A., Kumaki, K, and Poland, A. P., J. Cell. Physiol. 85:393, 1975.PubMedCrossRefGoogle Scholar
  24. 24.
    Baldwin, R. W., and Embleton, M. J., Int. J. Cancer 4:430, 1969.PubMedCrossRefGoogle Scholar
  25. 25.
    Hewitt, H. B., Blake, E. R., and Walder, A. S., Brit. J. Cancer 33:241, 1976.PubMedCrossRefGoogle Scholar
  26. 26.
    Embleton, M. J., and Heidelberger, C. L., Int. J. Cancer 9:8, 1972.PubMedCrossRefGoogle Scholar
  27. 27.
    Prehn, R. T., in “Immune Surveillance” (R. T. Smith and M. Landy, eds.), pp. 451–462, Academic Press, New York, 1970.Google Scholar
  28. 28.
    Parmiani, G., Carbone, G., and Prehn, R. T., J. Nat. Cancer Inst. 46:261, 1971.PubMedGoogle Scholar
  29. 29.
    Prehn, R. T., Int. J. Cancer 24:789, 1979.PubMedCrossRefGoogle Scholar
  30. 30.
    Prehn, R. T., Ann. N. Y. Acad. Sci. 164:449, 1969.PubMedCrossRefGoogle Scholar
  31. 31.
    Prehn, R. T., J. Nat. Cancer Inst. 31:791, 1963.PubMedGoogle Scholar
  32. 32.
    Evans, R., and Lawler, E. M., Int. J. Cancer 26:831, 1980.PubMedCrossRefGoogle Scholar
  33. 33.
    Evans, R., Brit. J. Cancer 35:557, 1977.PubMedCrossRefGoogle Scholar
  34. 34.
    Mantovani, A., Int. J. Cancer 22:741, 1978.PubMedCrossRefGoogle Scholar
  35. 35.
    Prehn, R. T., J. Nat. Cancer Inst. 59:1043, 1977.PubMedGoogle Scholar
  36. 36.
    Carrel, A., J. Exp. Med. 36:385, 1922.PubMedCrossRefGoogle Scholar
  37. 37.
    Burwell, R. G., Lancet 2:69, 1963.PubMedCrossRefGoogle Scholar
  38. 38.
    Burch, P. R. J., Nature 225:512, 1970.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Richmond T. Prehn
    • 1
  1. 1.Institute for Medical ResearchSan JoseUSA

Personalised recommendations